Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | MicrobiomeTrials← Back to trialsNCT07613099
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09-15Est. Completion: 2031-05-26
Enrollment target: 210 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia, Myelodysplasia-RelatedMyelodysplastic Syndrome
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific lab…
Birmingham, United StatesEst. completion May 15, 2029
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
CLL (Chronic Lymphocytic Leukemia)
Chronic Myeloid Leukemia (CML)
MDS (Myelodysplastic Syndrome)
Non-Hodgkin Lymphomas
Hodgkins Lymphoma
Cutaneous T Cell Lymphomas (CTCL)
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marro…
Duarte, United StatesEst. completion Jul 14, 2026
GATA2ImmunodeficiencyMDS
Background:
\- GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leu…
Bethesda, United StatesEst. completion Dec 31, 2027